← FDA DRUG APPROVALS

FDA NDA · NDA018705

NITROGLYCERIN

Sponsor: POHL BOSKAMP

APPLICATION
NDA018705
TYPE
NDA
ORIGINAL APPROVAL
1985-10-31
LATEST ACTION
2018-07-30
ROUTE
ORAL, SUBLINGUAL
DOSAGE FORM
AEROSOL, SPRAY, METERED
MARKETING STATUS
Discontinued, Prescription

Products

NITROLINGUALDiscontinued
NITROGLYCERIN 0.4MG/SPRAY · AEROSOL · SUBLINGUAL
NITROLINGUAL PUMPSPRAY · ReferencePrescription
NITROGLYCERIN 0.4MG/SPRAY · SPRAY, METERED · SUBLINGUAL

Approval history

2018-07-30Labeling · Supplement 25 · standardLetterAP
2016-09-02Labeling · Supplement 21 · standardAP
2016-04-21Manufacturing (CMC) · Supplement 20 · standardAP
2015-01-23Labeling · Supplement 19 · standardLetterAP
2008-10-01Manufacturing (CMC) · Supplement 17LabelAP
2006-09-28Labeling · Supplement 16 · standardLetterAP
2006-02-13Labeling · Supplement 15 · standardLetterAP
2004-09-02Labeling · Supplement 13 · standardLetterAP
2002-11-05Manufacturing (CMC) · Supplement 12 · standardLetterAP
1999-11-04Manufacturing (CMC) · Supplement 10 · standardAP
1999-11-04Manufacturing (CMC) · Supplement 9 · standardAP
1999-01-13Labeling · Supplement 8 · standardAP
1998-04-24Labeling · Supplement 7 · standardAP
1997-01-10Efficacy · Supplement 6 · standardAP
1995-01-11Labeling · Supplement 5 · standardAP
1990-03-02Manufacturing (CMC) · Supplement 4 · standardAP
1989-11-13Manufacturing (CMC) · Supplement 3 · standardAP
1988-12-02Labeling · Supplement 2AP
1986-04-23Labeling · Supplement 1AP
1985-10-31Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →